{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:56:15Z","timestamp":1790780175178,"version":"4.1.0"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the effects of naringenin on pathological, molecular, and behavioural alterations in a cuprizone-induced mouse model of demyelination, with particular emphasis on peroxisome proliferator-activated receptor (PPAR) gamma expression, NOD-like receptor family pyrin domain-containing 3 immunoreactivity, and molecular markers of myelin integrity, inflammation, and apoptosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Mice were allocated to four groups: control, naringenin alone, cuprizone, and cuprizone plus naringenin. Demyelination was induced with cuprizone-containing chow, and naringenin was administered orally for three weeks. Motor performance and biochemical, molecular, and histological changes were evaluated using established behavioural, immunological, molecular, and histological techniques.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>Naringenin improved motor deficits, increased myelin basic protein expression, reduced tumour necrosis factor-alpha, interleukin-1 beta, cyclooxygenase-2, prostaglandin E2, and nuclear factor kappa B p65 levels, and shifted apoptotic signalling towards cell survival by decreasing Bcl-2-associated X and increasing B-cell lymphoma 2 expression. Naringenin also increased PPAR gamma expression while reducing NOD-like receptor family pyrin domain-containing 3 immunoreactivity and suppressor of cytokine signalling 3 expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Naringenin attenuated cuprizone-induced brain inflammatory responses, apoptosis, and myelin injury, with findings consistent with modulation of PPAR gamma expression and NOD-like receptor family pyrin domain-containing 3-associated neuroinflammatory responses. These findings support further preclinical evaluation of naringenin for multiple sclerosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpp\/rgag113","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:52:01Z","timestamp":1788954721000},"source":"Crossref","is-referenced-by-count":0,"title":["Naringenin confers neuroprotection in a cuprizone-induced mouse model of multiple sclerosis with upregulation of PPAR-\u03b3 expression"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9318-0676","authenticated-orcid":false,"given":"Shereen F","family":"Behairy","sequence":"first","affiliation":[{"name":"Center for Nutritional Psychology , San Jos\u00e9, CA 95129 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3660-3981","authenticated-orcid":false,"given":"Mohamed I","family":"Fahmy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University of Science and Technology (MUST) , Giza 12566 ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5337-3658","authenticated-orcid":false,"given":"Rabab H","family":"Sayed","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University , Cairo 12613 ,","place":["Egypt"]},{"name":"Clinical Pharmacy Department, School of Pharmacy, Newgiza University , Giza 12563 ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed F","family":"El-Yamany","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University , Cairo 12613 ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"2026093010083726300_ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22074\/cellj.2016.4867","article-title":"Multiple sclerosis: pathogenesis, symptoms, diagnoses, and cell-based therapy","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell J"},{"key":"2026093010083726300_ref2","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1172\/jci58649","article-title":"Multiple sclerosis","volume":"122","author":"Nylander","year":"2012","journal-title":"J Clin Invest"},{"key":"2026093010083726300_ref3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/s1474-4422(18)30499-x","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"18","author":"Feigin","year":"2019","journal-title":"Lancet Neurol"},{"key":"2026093010083726300_ref4","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler J"},{"key":"2026093010083726300_ref5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.12998\/wjcc.v3.i7.545","article-title":"Treatment strategies for multiple sclerosis: when to start, when to change, when to stop?","volume":"3","author":"Gajofatto","year":"2015","journal-title":"World J Clin Cases"},{"key":"2026093010083726300_ref6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s11882-023-01102-0","article-title":"Multiple sclerosis pathogenesis and updates in targeted therapeutic approaches","volume":"23","author":"Vasileiou","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"key":"2026093010083726300_ref7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1600-0404.2008.01036.x","article-title":"The cuprizone model for demyelination","volume":"117","author":"Torkildsen","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"2026093010083726300_ref8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3390\/cells9040843","article-title":"The cuprizone model: dos and do nots","volume":"9","author":"Zhan","year":"2020","journal-title":"Cells"},{"key":"2026093010083726300_ref9","first-page":"691","volume-title":"Diseases Involving Myelin","author":"Staugaitis","year":"2012"},{"key":"2026093010083726300_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.119842","article-title":"Cuprizone-induced oligodendrocyte loss and demyelination impairs recording performance of chronically implanted neural interfaces","volume":"239","author":"Wellman","year":"2020","journal-title":"Biomaterials"},{"key":"2026093010083726300_ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.588516","article-title":"The protective effects of peroxisome proliferator-activated receptor gamma in cerebral ischemia-reperfusion injury","volume":"11","author":"Ding","year":"2020","journal-title":"Front Neurol"},{"key":"2026093010083726300_ref12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: a family of nuclear receptors in various diseases","volume":"2","author":"Tyagi","year":"2011","journal-title":"J Adv Pharm Technol Res"},{"key":"2026093010083726300_ref13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12974-023-02994-5","article-title":"Amelioration of experimental autoimmune encephalomyelitis by in vivo reprogramming of macrophages using pro-resolving factors","volume":"20","author":"Gauthier","year":"2023","journal-title":"J Neuroinflammation"},{"key":"2026093010083726300_ref14","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/brain\/aws058","article-title":"Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor gamma","volume":"135","author":"Hucke","year":"2012","journal-title":"Brain"},{"key":"2026093010083726300_ref15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.neuint.2013.06.012","article-title":"Peroxisome proliferator-activated receptor \u03b2\/\u03b4, a possible nexus of PPAR\u03b1- and PPAR\u03b3-dependent molecular pathways in neurodegenerative diseases: review and novel hypotheses","volume":"63","author":"Aleshin","year":"2013","journal-title":"Neurochem Int"},{"key":"2026093010083726300_ref16","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.bbrc.2016.08.043","article-title":"Peroxisome proliferator-activated receptors (PPARs) as therapeutic targets in neurodegenerative disorders","volume":"483","author":"Agarwal","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"2026093010083726300_ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.894298","article-title":"Focus on the role of the NLRP3 inflammasome in multiple sclerosis: pathogenesis, diagnosis, and therapeutics","volume":"15","author":"Cui","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"2026093010083726300_ref18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/bs.apcsb.2019.08.007","article-title":"Microglial NLRP3 inflammasome activation in multiple sclerosis","volume":"119","author":"Olcum","year":"2019","journal-title":"Adv Protein Chem Struct Biol"},{"key":"2026093010083726300_ref19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"2026093010083726300_ref20","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1093\/brain\/awaa135","article-title":"The NLRP3 inflammasome in progressive multiple sclerosis","volume":"143","author":"Kadowaki","year":"2020","journal-title":"Brain"},{"key":"2026093010083726300_ref21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/biom9110690","article-title":"On the neuroprotective effects of naringenin: pharmacological targets, signaling pathways, molecular mechanisms, and clinical perspective","volume":"9","author":"Nouri","year":"2019","journal-title":"Biomolecules"},{"key":"2026093010083726300_ref22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/ph12010011","article-title":"The therapeutic potential of naringenin: a review of clinical trials","volume":"12","author":"Salehi","year":"2019","journal-title":"Pharmaceuticals"},{"key":"2026093010083726300_ref23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cbi.2017.12.007","article-title":"Isolated mangiferin and naringenin exert antidiabetic effect via PPAR\u03b3\/GLUT4 dual agonistic action with strong metabolic regulation","volume":"280","author":"Singh","year":"2018","journal-title":"Chem Biol Interact"},{"key":"2026093010083726300_ref24","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s12640-018-9869-3","article-title":"Naringenin decreases \u03b1-synuclein expression and neuroinflammation in MPTP-induced Parkinson\u2019s disease model in mice","volume":"33","author":"Mani","year":"2018","journal-title":"Neurotox Res"},{"key":"2026093010083726300_ref25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neulet.2006.06.030","article-title":"Implications of protease M\/neurosin in myelination during experimental demyelination and remyelination","volume":"405","author":"Bando","year":"2006","journal-title":"Neurosci Lett"},{"key":"2026093010083726300_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111457","article-title":"Nicorandil attenuates cisplatin-induced acute kidney injury in rats via activation of PI3K\/AKT\/mTOR signaling cascade and inhibition of autophagy","volume":"127","author":"Fahmy","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2026093010083726300_ref27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.2042-7158.1968.tb09743.x","article-title":"The quantitative measurement of motor inco-ordination in naive mice using an accelerating rotarod","volume":"20","author":"Jones","year":"1968","journal-title":"J Pharm Pharmacol"},{"key":"2026093010083726300_ref28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrn2652","article-title":"Tests to assess motor phenotype in mice: a user\u2019s guide","volume":"10","author":"Brooks","year":"2009","journal-title":"Nat Rev Neurosci"},{"key":"2026093010083726300_ref29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"2026093010083726300_ref30","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"2026093010083726300_ref31","volume-title":"Theory and Practice of Histological Techniques","author":"Bancroft","year":"2008","edition":"6"},{"key":"2026093010083726300_ref32","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00401-009-0591-3","article-title":"The cuprizone animal model: new insights into an old story","volume":"118","author":"Kipp","year":"2009","journal-title":"Acta Neuropathol"},{"key":"2026093010083726300_ref33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.neubiorev.2014.10.004","article-title":"Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis","volume":"47","author":"Praet","year":"2014","journal-title":"Neurosci Biobehav Rev"},{"key":"2026093010083726300_ref34","doi-asserted-by":"publisher","article-title":"Naringenin improves muscle endurance via activation of the Sp1-ERR\u03b3 transcriptional axis","author":"Lv","DOI":"10.1016\/j.celrep.2023.113288"},{"key":"2026093010083726300_ref35","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.202100268","article-title":"Dietary naringenin preserves insulin sensitivity and grip strength and attenuates inflammation but accelerates weight loss in a mouse model of cancer cachexia","volume":"65","author":"Snoke","year":"2021","journal-title":"Mol Nutr Food Res"},{"key":"2026093010083726300_ref36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/WCO.0000000000000818","article-title":"Mechanisms underlying progression in multiple sclerosis","volume":"33","author":"Absinta","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"2026093010083726300_ref37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10753-019-01154-3","article-title":"Nateglinide exerts neuroprotective effects via downregulation of HIF-1\u03b1\/TIM-3 inflammatory pathway and promotion of caveolin-1 expression in the rat hippocampus subjected to focal cerebral ischemia\/reperfusion injury","volume":"43","author":"Saad","year":"2020","journal-title":"Inflammation"},{"key":"2026093010083726300_ref38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13024-022-00538-8","article-title":"Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of intrinsic and extrinsic causes of cuprizone demyelination","volume":"17","author":"Zirngibl","year":"2022","journal-title":"Mol Neurodegener"},{"key":"2026093010083726300_ref39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13024-024-00742-8","article-title":"The interplay of inflammation and remyelination: rethinking MS treatment with a focus on oligodendrocyte progenitor cells","volume":"19","author":"Zveik","year":"2024","journal-title":"Mol Neurodegener"},{"key":"2026093010083726300_ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111709","article-title":"Implication of M2 macrophage on NLRP3 inflammasome signaling in mediating the neuroprotective effect of canagliflozin against methotrexate-induced cognitive impairment","volume":"130","author":"Khedr","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2026093010083726300_ref41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pneurobio.2017.10.002","article-title":"Peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3): a master gatekeeper in CNS injury and repair","volume":"163-164","author":"Cai","year":"2017","journal-title":"Prog Neurobiol"},{"key":"2026093010083726300_ref42","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.2741\/2802","article-title":"Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-\u03b3 agonists","volume":"13","author":"Kapadia","year":"2007","journal-title":"Front Biosci"},{"key":"2026093010083726300_ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.1036655","article-title":"Naringenin, a citrus flavanone, enhances browning and brown adipogenesis: role of peroxisome proliferator-activated receptor gamma","volume":"9","author":"Bae","year":"2022","journal-title":"Front Nutr"},{"key":"2026093010083726300_ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2023.148563","article-title":"Naringin may promote functional recovery following spinal cord injury by modulating microglial polarization through the PPAR-\u03b3\/NF-\u03baB signaling pathway","volume":"1821","author":"Li","year":"2023","journal-title":"Brain Res"},{"key":"2026093010083726300_ref45","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.7150\/thno.46873","article-title":"Inhibitory effect of PPAR-\u03b3 on NLRP3 inflammasome activation","volume":"11","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"2026093010083726300_ref46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/2051-5960-1-43","article-title":"Myelin alters the inflammatory phenotype of macrophages by activating PPARs","volume":"1","author":"Bogie","year":"2013","journal-title":"Acta Neuropathol Commun"},{"key":"2026093010083726300_ref47","doi-asserted-by":"publisher","DOI":"10.1111\/jfbc.14415","article-title":"Naringenin: a prospective therapeutic agent for Alzheimer\u2019s and Parkinson\u2019s disease","volume":"46","author":"Goyal","year":"2022","journal-title":"J Food Biochem"},{"key":"2026093010083726300_ref48","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4103\/pm.pm_23_18","article-title":"Naringenin protects against 1-methyl-4-phenylpyridinium-induced neuroinflammation and reactive oxygen species production in SH-SY5Y cell line: an in vitro model of Parkinson\u2019s disease","volume":"14","author":"Mani","year":"2018","journal-title":"Pharmacogn Mag"},{"key":"2026093010083726300_ref49","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10072-013-1594-3","article-title":"Effect of naringenin on brain insulin signaling and cognitive functions in ICV-STZ-induced dementia model of rats","volume":"35","author":"Yang","year":"2013","journal-title":"Neurol Sci"},{"key":"2026093010083726300_ref50","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/658520","article-title":"PPAR regulation of inflammatory signaling in CNS diseases","volume":"2008","author":"Bright","year":"2008","journal-title":"PPAR Res"},{"key":"2026093010083726300_ref51","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/ijms19061639","article-title":"Metabolic dysfunction and peroxisome proliferator-activated receptors (PPAR) in multiple sclerosis","volume":"19","author":"Ferret-Sena","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026093010083726300_ref52","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/B978-0-444-52001-2.00004-2","article-title":"Demyelination in multiple sclerosis","volume":"122","author":"Lubetzki","year":"2014","journal-title":"In: Handb Clin Neurol"},{"key":"2026093010083726300_ref53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11910-021-01110-5","article-title":"Chronic demyelination and axonal degeneration in multiple sclerosis: pathogenesis and therapeutic implications","volume":"21","author":"Simkins","year":"2021","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2026093010083726300_ref54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2103084118","article-title":"PPAR-\u03b3 activation enhances myelination and neurological recovery in premature rabbits with intraventricular hemorrhage","volume":"118","author":"Krishna","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026093010083726300_ref55","doi-asserted-by":"publisher","first-page":"9329","DOI":"10.3390\/ijms21239329","article-title":"Altered PPAR-\u03b3 expression promotes myelin-induced foam cell formation in macrophages in multiple sclerosis","volume":"21","author":"Wouters","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026093010083726300_ref56","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/NEN.0b013e3181aba2c1","article-title":"Peroxisome proliferator-activated receptor-\u03b3 agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells","volume":"68","author":"Bernardo","year":"2009","journal-title":"J Neuropathol Exp Neurol"},{"key":"2026093010083726300_ref57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2120393119","article-title":"Phloretin enhances remyelination by stimulating oligodendrocyte precursor cell differentiation","volume":"119","author":"Dierckx","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026093010083726300_ref58","doi-asserted-by":"publisher","first-page":"470","DOI":"10.4103\/1673-5374.202923","article-title":"The mechanism of naringin-enhanced remyelination after spinal cord injury","volume":"12","author":"Rong","year":"2017","journal-title":"Neural Regen Res"},{"key":"2026093010083726300_ref59","doi-asserted-by":"publisher","first-page":"7584","DOI":"10.3390\/ijms23147584","article-title":"The possible role of neural cell apoptosis in multiple sclerosis","volume":"23","author":"Kennedy","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026093010083726300_ref60","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jneuroim.2015.08.016","article-title":"Role of inflammation and apoptosis in multiple sclerosis: comparative analysis between the periphery and the central nervous system","volume":"287","author":"Macchi","year":"2015","journal-title":"J Neuroimmunol"},{"key":"2026093010083726300_ref61","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"2026093010083726300_ref62","doi-asserted-by":"publisher","first-page":"37006","DOI":"10.1074\/jbc.M700447200","article-title":"Peroxisome proliferator-activated receptor \u03b3 up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis","volume":"282","author":"Fuenzalida","year":"2007","journal-title":"J Biol Chem"},{"key":"2026093010083726300_ref63","doi-asserted-by":"publisher","first-page":"G133","DOI":"10.1152\/ajpgi.00262.2009","article-title":"Liver apoptosis is age dependent and is reduced by activation of peroxisome proliferator-activated receptor-\u03b3 in hemorrhagic shock","volume":"298","author":"Zingarelli","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2026093010083726300_ref64","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.biopha.2017.05.112","article-title":"Naringenin protects keratinocytes from oxidative stress injury via inhibition of the NOD2-mediated NF-\u03baB pathway in pemphigus vulgaris","volume":"92","author":"Liang","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"2026093010083726300_ref65","doi-asserted-by":"publisher","DOI":"10.1590\/acb380823","article-title":"Naringenin attenuates cerebral ischemia\/reperfusion injury by inhibiting oxidative stress and inflammatory responses via the activation of SIRT1\/FOXO1 signaling pathway in vitro","volume":"38","author":"Zhao","year":"2023","journal-title":"Acta Cir Bras"},{"key":"2026093010083726300_ref66","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fimmu.2017.00070","article-title":"Dysregulation of SOCS-mediated negative feedback of cytokine signaling in carcinogenesis and its significance in cancer treatment","volume":"8","author":"Jiang","year":"2017","journal-title":"Front Immunol"},{"key":"2026093010083726300_ref67","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1089\/jir.2014.0012","article-title":"Involvement of the Janus kinase\/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis","volume":"34","author":"Benveniste","year":"2014","journal-title":"J Interf Cytokine Res"},{"key":"2026093010083726300_ref68","doi-asserted-by":"publisher","first-page":"7859","DOI":"10.1073\/pnas.0602574103","article-title":"Suppressor of cytokine signaling 3 limits protection of leukemia inhibitory factor receptor signaling against central demyelination","volume":"103","author":"Emery","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026093010083726300_ref69","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.mcn.2006.01.005","article-title":"SOCS3 negatively regulates LIF signaling in neural precursor cells","volume":"31","author":"Emery","year":"2006","journal-title":"Mol Cell Neurosci"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/9\/rgag113\/71523270\/rgag113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/9\/rgag113\/71523270\/rgag113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:08:43Z","timestamp":1790777323000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/doi\/10.1093\/jpp\/rgag113\/8853861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgag113","relation":{},"ISSN":["2042-7158"],"issn-type":[{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"rgag113"}}